Indivior Shifts Primary Listing from London to Nasdaq

Published 1 days agoINDV

Indivior Shifts Primary Listing from London to Nasdaq

Indivior PLC, known for its specialty in treatments for substance use disorders, is set to change its primary stock market listing from the London Stock Exchange (LSE) to the Nasdaq Stock Market. The move follows overwhelming shareholder approval, with the transition officially taking effect on June 27, 2024. As reported by Nasdaq, this decision marks a significant step for the company as it aligns its operations closer to its primary market.

Despite this shift, Indivior will retain a secondary listing on the LSE, ensuring UK investors remain engaged with the company. This dual listing strategy allows Indivior to leverage its existing investor base in the United Kingdom while predominantly trading in its most lucrative market. According to Shares Magazine, the new Nasdaq primary listing reflects the company's concentration on maximizing opportunities in the U.S.

Indivior generates around 81% of its sales in the United States, underscoring the strategic rationale for the move. As City A.M. notes, this transition also mirrors a wider trend of UK firms considering primary listings in the U.S., which could have long-term implications for the competitiveness of London's financial markets. Indivior's shift to Nasdaq demonstrates its intent to capitalize on growth opportunities within its largest market sector.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Citigroup Lifts Restrictions on Firearm-Linked Retail Clients

Citigroup Lifts Restrictions on Firearm-Linked Retail Clients

13 minutes agoC

Citigroup is set to reverse its 2018 policy that limited banking services for retail clients engaged in the sale of firearms. This decision reflects a strategic shift in response to changing regulatory landscapes and growing scrutiny over the fair treatment of certain industries. The rollback marks a significant policy change for Citigroup as it aims to address ongoing debates around corporate policies and social causes. Reuters reported that Citigroup’s move comes as a reaction to regulatory adjustments and heightened attention on equitable access to financial services. The company is also updating its employee code of conduct along with its customer financial access policy, emphasizing a non-discriminatory stance regardless of political ties. This aligns with a broader industry trend to enhance transparency and fairness amidst accusations of bias against specific sectors or political ideologies. Citigroup's change in policy arrives amid a politically charged environment, which includes criticisms from figures like former President Donald Trump over corporate involvements in social issues and banking biases related to political orientations. While the bank has discontinued specific restrictions, it holds an optimistic view that communities and lawmakers will continue striving to address gun violence concerns, as reported by the Financial Times.

Moderna to Launch Placebo-Controlled Trial for New COVID-19 Vaccine

Moderna to Launch Placebo-Controlled Trial for New COVID-19 Vaccine

28 minutes agoMRNA

On June 3, 2025, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced that Moderna will conduct a placebo-controlled trial for its latest COVID-19 vaccine, mNEXSPIKE. This decision comes as part of efforts to address public concerns over the vaccine's safety and efficacy. The trial is designed to enhance transparency and scientific rigor, ensuring robust evaluation of the vaccine. Moderna's mNEXSPIKE, the next-generation COVID-19 vaccine, recently received FDA approval for use in adults aged 65 and older, as well as those aged 12 to 64 with underlying health conditions. Reuters reported that the FDA's oversight will include closely monitoring the trial for any adverse outcomes, aiming to uphold trust in the vaccination program. Previously, Moderna's vaccines have shown a 94.1% efficacy rate in preventing symptomatic COVID-19, with no severe cases among those vaccinated. The decision to enforce a placebo-controlled trial aligns with recent regulatory changes by the FDA, reflecting stricter standards for vaccine approvals. These changes particularly focus on the necessity for comprehensive research, especially for healthy adults under 65. With these developments, the emphasis remains on maintaining high safety and efficacy standards for COVID-19 vaccines through detailed scientific evaluation.

Meta Enters 20-Year Deal for Nuclear Power with Constellation Energy

Meta Enters 20-Year Deal for Nuclear Power with Constellation Energy

58 minutes agoMETA

Meta Platforms has inked a 20-year power purchase agreement with Constellation Energy to support the Clinton Clean Energy Center, a nuclear power plant in Illinois. This deal is a multibillion-dollar proposal, though specific financial terms remain undisclosed, as reported by Axios. Such a long-term agreement signifies Meta's commitment to securing sustainable energy sources for its operations. The Clinton plant, capable of producing 1.1 gigawatts of electricity, will now continue providing zero-carbon energy to the regional grid. This move comes as tech giants like Meta look to nuclear power to sustainably meet the high energy needs that come with expanding artificial intelligence technologies. The plant's output will increase by 30 megawatts, adding enough electricity to power a city of 30,000 people, according to an AP News report. Beyond energy production, the agreement carries significant economic implications for the local community, preserving 1,100 jobs, and generating $13.5 million in annual tax revenue, noted the Financial Times. This partnership illustrates a growing trend within the tech industry to integrate nuclear energy into their energy strategies as they scale AI and other technologies.

Post Holdings Acquires 8th Avenue for $880 Million

Post Holdings Acquires 8th Avenue for $880 Million

1 hours agoPOST

Post Holdings has announced an agreement to acquire 8th Avenue Food & Provisions in a transaction valued at $880 million, which includes the assumption of existing debt. This strategic acquisition keeps Post Holdings with a 60.5% ownership stake, while Thomas H. Lee Partners, L.P. will hold the remaining 39.5%, as reported by bakingbusiness.com. James E. Dwyer, who has led the private brands division of Post Holdings since early 2018, will continue in his role as president and CEO of 8th Avenue. The proceeds from the acquisition are expected to help reduce Post Holdings' term loan, boosting its financial leverage ratio, according to further details shared by bakingbusiness.com. The acquisition of 8th Avenue is aligned with Post Holdings' strategy to concentrate on its core operations while maintaining a significant interest in the private brands market through 8th Avenue. This move supports the company's broader objective to optimize its portfolio and enhance its positioning in the competitive food products sector.